Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii

  1. Irini Pateraki  Is a corresponding author
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
  1. University of Copenhagen, Denmark
  2. University of California, Berkeley, United States
  3. Evolva, Denmark
  4. Nofima, Norway
  5. KTH - Royal Institute of Technology, Sweden
  6. Michigan State University, United States

Abstract

Forskolin is a unique structurally complex labdane type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Here we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13R-manoyl oxide into forskolin and a diverse array of additional labdane-type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13R-manoyl oxide into forskolin as demonstrated by transient expression in Nicotiana benthamiana. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into Saccharomyces cerevisiae and afforded forskolin titers of 40 mg/L.

Article and author information

Author details

  1. Irini Pateraki

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    For correspondence
    eipa@plen.ku.dk
    Competing interests
    Irini Pateraki, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7526-2334
  2. Johan Andersen-Ranberg

    Department of Plant and Microbial Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    Johan Andersen-Ranberg, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  3. Niels Bjerg Jensen

    Evolva, Copenhagen, Denmark
    Competing interests
    Niels Bjerg Jensen, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compoundsEmployee of Evolva SA.
  4. Sileshi Gizachew Wubshet

    Nofima, Osloveien, Norway
    Competing interests
    No competing interests declared.
  5. Allison Maree Heskes

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2732-5185
  6. Victor Forman

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  7. Björn Hallström

    Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  8. Britta Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    No competing interests declared.
  9. Mohammed Saddik Motawia

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  10. Carl Erik Olsen

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  11. Dan Staerk

    Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  12. Jørgen Hansen

    Evolva, Copenhagen, Denmark
    Competing interests
    Jørgen Hansen, Employee of Evolva SA.
  13. Birger Lindberg Møller

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    Birger Lindberg Møller, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  14. Bjoern Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    Bjoern Hamberger, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds'.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1249-1807

Funding

Villum Fonden

  • Birger Lindberg Møller

Novo Nordisk

  • Birger Lindberg Møller

European Commission

  • Irini Pateraki

DOE Office of Science (BER DE-FC02-07ER64494)

  • Bjoern Hamberger

Strategic Partnership Grant (15-SPG-Full-3101)

  • Bjoern Hamberger

MSU Foundation

  • Bjoern Hamberger

Michigan State University (startup funding from the Department of Molecular Biology and Biochemistry)

  • Bjoern Hamberger

Michigan State University (AgBioResearch - MICL02454)

  • Bjoern Hamberger

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Pateraki et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,151
    views
  • 821
    downloads
  • 99
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Irini Pateraki
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
(2017)
Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii
eLife 6:e23001.
https://doi.org/10.7554/eLife.23001

Share this article

https://doi.org/10.7554/eLife.23001

Further reading

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Federico A Vignale, Andrea Hernandez Garcia ... Adrian G Turjanski
    Research Article

    Yerba mate (YM, Ilex paraguariensis) is an economically important crop marketed for the elaboration of mate, the third-most widely consumed caffeine-containing infusion worldwide. Here, we report the first genome assembly of this species, which has a total length of 1.06 Gb and contains 53,390 protein-coding genes. Comparative analyses revealed that the large YM genome size is partly due to a whole-genome duplication (Ip-α) during the early evolutionary history of Ilex, in addition to the hexaploidization event (γ) shared by core eudicots. Characterization of the genome allowed us to clone the genes encoding methyltransferase enzymes that catalyse multiple reactions required for caffeine production. To our surprise, this species has converged upon a different biochemical pathway compared to that of coffee and tea. In order to gain insight into the structural basis for the convergent enzyme activities, we obtained a crystal structure for the terminal enzyme in the pathway that forms caffeine. The structure reveals that convergent solutions have evolved for substrate positioning because different amino acid residues facilitate a different substrate orientation such that efficient methylation occurs in the independently evolved enzymes in YM and coffee. While our results show phylogenomic constraint limits the genes coopted for convergence of caffeine biosynthesis, the X-ray diffraction data suggest structural constraints are minimal for the convergent evolution of individual reactions.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.